$GeoVax Labs (GOVX.US)$shares have surged over 225% in the past week, continuing to rally Monday. This spike comes after the World Health Organization (WHO) declared a public health emergency due to an mpox outbreak in Africa. The WHO's concern over the rapid spread of a new mpox clade in the region has prompted calls for an international response.
GeoVax, a clinical-stage biotech company, is focused on developing immunotherapies and vaccines...

$Novavax (NVAX.US)$
In 2024, Novavax's development reached a new climax, and the company's stock price and business development showed impressive performance. From a $1.2 billion vaccine license agreement with Sanofi to plans to promote its JN.1 protein-based non-mRNA COVID-19 vaccine globally, Novavax has certainly taken a place in the global biotech industry. In this context, many investors may be asking: is Novavax's stock still worth buying at the current price of $8-10?
Strong market dynamics
Novavax not only soared more than 99% in the first quarter of 2024, but also announced strong financial results. All of this further strengthened the market's confidence in its business model after the company reached a major vaccine licensing agreement with Sanofi. This type of collaboration provides a continuous revenue stream, while also showing Novavax's competitiveness and brand influence in the global vaccine market.
Innovative vaccine development
Additionally, the World Health Organization (WHO) recommended Novavax's JN.1 COVID-19 vaccine, which not only recognized its technology and product effectiveness, but also opened the door to the upcoming fall vaccine market. According to the company's latest non-clinical data, JN...